Abstract
Objective To explore the effect of edaravone combined with anticoagulant therapy on the serum hs-CRP, IL-6, and TNF-α levels and the activity of daily living (ADL) in patients with acute cerebral infarction (ACI). Methods The clinical data of 84 ACI patients treated in our hospital from August 2020 to August 2021 were retrospectively analyzed, and they were divided into the routine group (n = 42) and the combined group (n = 42) according to the order of admission. Both groups were treated with routine clinical treatment, and the combined group was additionally treated with edaravone combined with anticoagulant therapy. Serum samples were collected from both groups after treatment. ELISA was used to detect the serum inflammatory factor levels, and the modified Barthel index score was used to evaluate the ADL of patients. Results Compared with the routine group, the combined group achieved obviously lower levels of PMA, CD62p, and serum inflammatory factors after treatment (P < 0.001), higher modified Barthel score after treatment (P < 0.001), lower plasma viscosity, platelet aggregation rate, and plasma fibrinogen level after treatment (P < 0.001), and higher clinical overall efficacy (P < 0.05). Conclusion Edaravone combined with anticoagulant therapy is a reliable method to enhance ADL and reduce the inflammatory response of ACI patients. This strategy greatly reduces the platelet-activating factor levels of patients and improves the comprehensive clinical efficacy, and its further research will help to establish a better solution for these patients.
Highlights
Acute cerebral infarction (ACI) refers to brain tissue necrosis caused by the sudden interruption of cerebral blood supply, with complicated pathogenesis [1]
As a common and frequently-occurring disease in clinic, ACI is characterized by high morbidity, mortality, disability, and recurrence. e abnormal blood supply of local brain tissues caused by various factors leads to brain tissue lesions and damages the brain tissues, triggering ACI
ACI is mainly treated with anticoagulation, thrombolysis, and lipid-lowering to stabilize plaques. e common side effect of thrombolytic therapy is bleeding, which can manifest as skin and mucosa bleeding in patients with mild symptoms and visceral hemorrhage, such as gastrointestinal bleeding and brain bleeding, in patients with severe symptoms
Summary
To explore the effect of edaravone combined with anticoagulant therapy on the serum hs-CRP, IL-6, and TNF-α levels and the activity of daily living (ADL) in patients with acute cerebral infarction (ACI). E clinical data of 84 ACI patients treated in our hospital from August 2020 to August 2021 were retrospectively analyzed, and they were divided into the routine group (n 42) and the combined group (n 42) according to the order of admission. Both groups were treated with routine clinical treatment, and the combined group was treated with edaravone combined with anticoagulant therapy. Edaravone combined with anticoagulant therapy is a reliable method to enhance ADL and reduce the inflammatory response of ACI patients. is strategy greatly reduces the platelet-activating factor levels of patients and improves the comprehensive clinical efficacy, and its further research will help to establish a better solution for these patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
